Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Cantharidin (Primary)
  • Indications Molluscum contagiosum
  • Focus Registrational; Therapeutic Use
  • Acronyms CAMP-1
  • Sponsors Verrica Pharmaceuticals
  • Most Recent Events

    • 03 Jan 2019 According to a Verrica Pharmaceuticals media release, primary endpoint (Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions on the Day 84 visit) has been met.
    • 03 Jan 2019 According to a Verrica Pharmaceuticals media release, data from CAMP-1 and CAMP-2 studies will provide a strong foundation of NDA which is planned to submit in the second half of 2019.
    • 03 Jan 2019 According to a Verrica Pharmaceuticals media release, this trial is conducted under an FDA Special Protocol Assessment (SPA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top